Fairvalue-Calculator Fairvalue-Calculator

Chugai Pharmaceutical Co (CHGCF) Fair Value & Analysis

Healthcare · US · Market cap $75.6B

Price$44.23
Fair Value$33.65
Upside-23.9%
Quality95/100
Evidence: High Range $20.29 – $42.96

Analysis

Chugai Pharmaceutical Co (CHGCF) currently trades at $44.23, while our model-based Fair Value estimate is $33.65 — implying the stock looks roughly 23.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1…

Open the full interactive analysis →

Similar stocks

Eli Lilly and Company (LLY) -60% Johnson & Johnson, (JNJ) -23% AbbVie Inc (ABBV) -52% Roche Holding (ROGN) -20% Merck & Co (MRK) -45% AstraZeneca PLC (A1ZN34) -85%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.